BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Delpacibart zotadirsen readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Delpacibart zotadirsen\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06244082-11262@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Delpacibart zotadirsen: Phase 2 readout est. (NCT06244082)
DESCRIPTION:Delpacibart zotadirsen\, phase 2\, Duchenne Muscular Dystrophy.
 \nStudy: Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy P
 articipants With Mutations Amenable to Exon44 Skipping\nEstimated primary 
 completion: 30 April 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/delpacibart-zotadirsen#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06244082
URL:https://assetmemo.bio/drug/delpacibart-zotadirsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07587242-11262@assetmemo.bio
DTSTAMP:20261121T005036Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Delpacibart zotadirsen: Phase 3 readout est. (NCT07587242)
DESCRIPTION:Delpacibart zotadirsen\, phase 3.\nStudy: A Phase 3 Study to Ev
 aluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibar
 t Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exo
 n 44 Skipping\nEstimated primary completion: May 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/delpacibart-zotadirsen#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07587242
URL:https://assetmemo.bio/drug/delpacibart-zotadirsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
